FTC demands Alzheimer’s drug approval, marketing information from Biogen

Biogen Inc. disclosed in an annual filing Thursday night that the Federal Trade Commission has issued an civil investigative demand for information on the company’s controversial Alzheimer’s disease drug that was approved last year.